References
- World Health Organization. Human papillomavirus and cervical cancer. Reprod Health Matters [Internet]. 2000;8:190. [accessed 2018 May 31]. http://linkinghub.elsevier.com/retrieve/pii/S0968808000902593.
- Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer [Internet]. 2018;18:240–54. [accessed 2018 May 31]. http://www.nature.com/doifinder/10.1038/nrc.2018.13.
- Zhai L, Tumban E. Gardasil-9: a global survey of projected efficacy. Antiviral Res [Internet]. 2016;130:101–09. [accessed 2018 May 31]. https://www.sciencedirect.com/science/article/pii/S0166354216300377?via%3Dihub.
- Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al. The global burden of cancer 2013. JAMA Oncol [Internet]. 2015;1:505–27. [accessed 2018 May 31]. http://www.ncbi.nlm.nih.gov/pubmed/26181261.
- Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med [Internet]. 2003;348:518–27. [accessed 2018 May 31]. http://www.nejm.org/doi/abs/10.1056/NEJMoa021641.
- Merck. FDA approves Merck’s HPV vaccine, GARDASIL®9, to prevent cancers and other diseases caused by nine HPV types – including types that cause about 90% of cervical cancer cases [Internet]. 2014 [accessed 2018 May 31]. http://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-hpv-vaccine-gardasil9-prevent-cancers-an.
- Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muñoz J, et al. ICO Information Centre on HPV and cancer (HPV Information Centre). Human papillomavirus and related diseases in [Botswana] [Internet]. 2014. [accessed 2019 April 3] http://www.hpvcentre.net/statistics/reports/XWX.pdf.
- Cervical Cancer Action. Progress in cervical cancer prevention: the CCA report card [Internet]. 2011. [accessed 2019 April 3] http://www.paho.org/hq/dmdocuments/2011/CCA_reportcard_low-res.pdf.
- Gallagher KE, Erio T, Baisley K, Lees S, Watson-Jones D. The impact of a human papillomavirus (HPV) vaccination campaign on routine primary health service provision and health workers in Tanzania: a controlled before and after study. BMC Health Serv Res [Internet]. 2018;18:173. [accessed 2018 Jun 8]. http://www.ncbi.nlm.nih.gov/pubmed/29530042.
- CDC. CDC vaccine price list [Internet]. CDC. 2015. p. 1–7. [accessed 2018 Jun 5]. http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/.
- Clendinen C, Zhang Y, Warburton RN, Light DW. Manufacturing costs of HPV vaccines for developing countries. Vaccine [Internet]. 2016;34:5984–89. [accessed 2018 Jun 8]. https://www.sciencedirect.com/science/article/pii/S0264410X16308568.
- MSF. The right shot: bring down barriers to affordable and adapted vaccines. 2015. Geneva, Switzerland: MSF Access Campaign.
- World Health Organization (WHO). Vaccines and biologicals. The Department of Immunization. Monitoring vaccine wastage at country level – guidelines for programme managers [Internet]. Geneva. 2003. [accessed 2019 April 3]https://apps.who.int/iris/bitstream/handle/10665/68463/WHO_VB_03.18.Rev.1_eng.pdf.
- Merck. Gardasil-9, human papillomavirus 9-valent vaccine, recombinant-storage and handling [Internet]. 2018 [accessed 2018 May 31]. https://www.merckvaccines.com/Products/Gardasil9/storage/temperature-excursions.
- World Health Organization. Controlled Temperature Chain (CTC) [Internet]. 2016. [accessed 2018 May 13] http://www.who.int/biologicals/areas/vaccines/controlledtemperaturechain/en/.
- Kunda NK, Somavarapu S, Gordon SB, Hutcheon GA, Saleem IY. Nanocarriers targeting dendritic cells for pulmonary vaccine delivery. Pharm Res [Internet]. 2013;30:325–41. doi:10.1007/s11095-012-0891-5.
- Kanojia G, Willems G-J, Frijlink HW, Kersten GFA, Soema PC, Amorij J-P. A design of experiment approach to predict product and process parameters for a spray dried influenza vaccine. Int J Pharm [Internet]. 2016;511:1098–111. doi:10.1016/j.ijpharm.2016.08.022.
- Afkhami S, LeClair DA, Haddadi S, Lai R, Toniolo SP, Ertl HC, Cranston ED, Thompson MR, Xing Z. Spray dried human and chimpanzee adenoviral-vectored vaccines are thermally stable and immunogenic in vivo. Vaccine. 2017;35:2916–24. doi:10.1016/j.vaccine.2017.04.026.
- Kanojia G, ten Have R, Soema PC, Frijlink H, Amorij J-P, Kersten G. Developments in the formulation and delivery of spray dried vaccines. Hum Vaccin Immunother. 2017;13:2364–78. doi:10.1080/21645515.2017.1356952.
- Kunda NK, Wafula D, Tram M, Wu TH, Muttil P. A stable live bacterial vaccine. Eur J Pharm Biopharm. 2016;103:109–17. doi:10.1016/j.ejpb.2016.03.027.
- Garcia-Contreras L, Wong Y-L, Muttil P, Padilla D, Sadoff J, DeRousse J, Germishuizen WA, Goonesekera S, Elbert K, Bloom BR, et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci [Internet]. 2008;105:4656–60. [accessed 2019 April 3] http://www.pnas.org/cgi/doi/10.1073/pnas.0800043105.
- Saboo S, Tumban E, Peabody J, Wafula D, Peabody DS, Chackerian B, Muttil P. Optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus. Mol Pharm [Internet]. 2016;13:1646–55. [accessed 2018 Jun 1]. http://www.ncbi.nlm.nih.gov/pubmed/27019231.
- Price DN. Pulmonary BCG vaccination for uniform protection against tuberculosis in environmental mycobacteria endemic regions. 2016.
- Peabody J, Muttil P, Chackerian B, Tumban E. Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature. Papillomavirus Res [Internet]. 2017;3:116–20. [accessed 2018 Jun 1]. https://www.sciencedirect.com/science/article/pii/S2405852116301173?via%3Dihub#s0010.
- Tumban E, Muttil P, Escobar CAA, Peabody J, Wafula D, Peabody DS, Chackerian B. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Vaccine [Internet]. 2015;33:3346–53. [accessed 2015 Jul 13]. https://www.sciencedirect.com/science/article/pii/S0264410X15006374?via%3Dihub#sec0010.
- Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med [Internet]. 2007;13:857–61. [accessed 2018 Jun 22]. http://www.nature.com/articles/nm1598.
- Daniyal M, Akhtar N, Ahmad S, Fatima U, Akram M, Asif HM. Update knowledge on cervical cancer incidence and prevalence in Asia. Asian Pacific J Cancer Prev [Internet]. 2015;16:3617–20. [accessed 2018 Jun 18]. http://www.ncbi.nlm.nih.gov/pubmed/25987011.
- Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin DB. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals [Internet]. 2014;42:237–59. [accessed 2015 May 13]. http://www.ncbi.nlm.nih.gov/pubmed/24996452.
- Lydon P, Zipursky S, Tevi-Benissan C, Djingarey MH, Gbedonou P, Youssouf BO, Zaffran M. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Bull World Health Organ [Internet]. 2014;92:86–92. [accessed 2018 June 8] http://www.who.int/entity/bulletin/volumes/92/2/13-123471.pdf.
- Zaffran M, Vandelaer J, Kristensen D, Melgaard B, Yadav P, Antwi-Agyei KO, Lasher H. The imperative for stronger vaccine supply and logistics systems. Vaccine [Internet]. 2013;31:B73–80. [accessed 2018 Jun 5]. https://www.sciencedirect.com/science/article/pii/S0264410X12016295?via%3Dihub#bib0100.
- WHO Immunization Practices Advisory Committee. Immunization supply chain and logistics: a neglected but essential system for national immunization programmes [Internet]. Geneva. 2014. [accessed 2019 April 3] http://www.who.int/immunization/sage/meetings/2014/april/presentations_background_docs/en/.
- Kristensen DD, Lorenson T, Bartholomew K, Villadiego S. Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries. Vaccine [Internet]. 2016;34:899–904. [accessed 2018 Jun 5]. http://dx.doi.org/10.1016/j.vaccine.2016.01.001.
- Dairo DM, Osizimete OE. Factors affecting vaccine handling and storage practices among immunization service providers in Ibadan, Oyo State, Nigeria. Afr Health Sci [Internet]. 2016;16:576–83. [accessed 2018 Jun 5]. http://www.ncbi.nlm.nih.gov/pubmed/27605974.
- Kunda NK, Alfagih IM, Miyaji EN, Figueiredo DB, Gonçalves VM, Ferreira DM, Dennison SR, Somavarapu S, Hutcheon GA, Saleem IY. Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles. Int J Pharm [Internet]. 2015;495:903–12. [accessed 2015 Sep 29]. http://www.sciencedirect.com/science/article/pii/S0378517315302325.
- Lu D, Garcia-Contreras L, Muttil P, Padilla D, Xu D, Liu J, Braunstein M, McMurray DN, Hickey AJ. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J [Internet]. 2010;12:338–47. [accessed 2018 June 8] http://www.springerlink.com/index/10.1208/s12248-010-9193-1.
- Zhai L, Peabody J, Pang YYS, Schiller J, Chackerian B, Tumban E. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Antiviral Res [Internet]. 2017;147:116–23. [accessed 2018 Jun 8]. https://www.sciencedirect.com/science/article/pii/S0166354217305168?via%3Dihub.
- Tumban E, Peabody J, Peabody DS, Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One [Internet]. 2011;6:e23310. [accessed 2018 Jun 1]. http://dx.plos.org/10.1371/journal.pone.0023310.